Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Aesculap Biologics Launches New Website


CENTER VALLEY, Pa., Dec. 11, 2017 /PRNewswire/ -- Aesculap Biologics, LLC is pleased to announce the launch of its redesigned website. The new website has a clean, uncluttered design, improved functionality, and enhanced rich content to provide both healthcare professionals and patients with essential information about the NOVOCART® 3D Phase 3 clinical trial.

Aesculap Biologics, LLC was established in January 2012 as a new company focused on biological approaches to the repair and regeneration of diseased or damaged tissues. Using a combination of cells, growth factors and smart biomaterial devices, Aesculap Biologics products are intended to stimulate and support the synthesis of new tissue and enhance the body's own regenerative power.

The Phase 3 trial Aesculap Biologics is currently conducting is working to bring NOVOCART® 3D to the U.S. from Europe, where it originated and has been implanted in more than 9,000 patients since 2003. NOVOCART 3D is a tissue engineered cell-based product designed to repair articular cartilage defects of the knee. Future Aesculap Biologics products under development will focus on a similar approach to treating back pain, the second most common neurological ailment in the US.

The development of regenerative products, such as NOVOCART 3D, requires a diverse range of expertise. Aesculap Biologics is comprised of a group of professionals with experience in cell and molecular biology, clinical trial management, cell-based product manufacturing, materials management, quality assurance and control, and regulatory affairs. Biologic approaches to tissue repair and regeneration represent the future in healthcare worldwide. Aesculap Biologics' mission ensures that we will be ready for the challenge.

About Aesculap Biologics, LLC
Aesculap Biologics, LLC, was established in January 2012 as a division of Aesculap, Inc. and is focused on biological approaches to the repair and regeneration of diseased or damaged tissues. Using a combination of cells, growth factors and smart biomaterial devices, Aesculap Biologics products can stimulate and support the synthesis of new tissue and enhance the body's own regenerative power to improve the quality of patients' lives.

SOURCE Aesculap Biologics, LLC


These press releases may also interest you

at 09:30
Aurionpro Solutions Limited (BSE: 532668) (NSE: AURIONPRO) announces the acquisition of Banking and Insurance focused PaaS startup, Arya.ai. With Arya.ai, Aurionpro will enhance its portfolio of enterprise fintech offerings to expedite adoption of AI...

at 07:47
Aurionpro Solutions Limited (BSE: 532668) (NSE: AURIONPRO) announces the acquisition of Banking and Insurance focused PaaS startup, Arya.ai. With Arya.ai, Aurionpro will enhance its portfolio of enterprise fintech offerings to expedite adoption of AI...

at 07:28
BioArctic AB (publ) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransportertm technology with an...

at 06:00
OKX, a leading Web3 technology company, today announced that it now supports deposits and withdrawals of ORDI and SATS tokens on the Merlin Chain. This integration expands the range of networks available to OKX users for managing these key Web3...

at 05:00
Shoplooks, an industry-leading influencer network, celebrates another milestone achievement after being recognized at the US Partnership Awards (USPA) 2024. Shoplooks won the Best Content Partnership Award for its influencer marketing campaign with...

at 03:36
OKX, a leading Web3 technology company, today announced an exciting partnership between its OKX Wallet and Ethena, an Ethereum-based synthetic dollar protocol, to launch the Ethena USDe Bonus Event....



News published on and distributed by: